What are the treatment options for colorectal cancer? - Dr. Tanios Bekaii-Saab

(1:7)

Tanios Bekaii-Saab, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

(1:22)

Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

(1:27)

Tanios Bekaii-Saab, MD: Mechanisms of Action in Regorafenib

(1:12)

Tanios Bekaii-Saab, MD, FACP, offers opinion on the updated KEYNOTE-177 as presented at ASCO GI 2021

(4:39)

Tanios Bekaii-Saab, MD, discusses oral chemo in adjuvant and advanced CRC treatment during COVID

(3:16)

Tanios Bekaii Saab, MD: Treatment Toxicities and Quality of Life

(2:56)

Tanios Bekaii-Saab, MD: Bevacizumab Side-Effects

(2:21)

Tanios Bekaii Saab, MD: RAS Mutations and the Sequence of Therapies

(5:8)

Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

(1:59)

Tanios Bekaii-Saab, MD: Chemotherapy Side-Effects

(2:13)

Tanios Bekaii-Saab, MD: First-Line Treatments in Unresectable Colon Cancer

(2:17)

Emerging Role of HER2-Targeted Therapy in BTCs — Tanios Bekaii-Saab, MD

(32:21)

Dr Bekaii-Saab on Frontline Treatment Considerations for BRCA1/2+ Pancreatic Cancer

(1:45)

Tanios Bekaii-Saab MD, FACP describes deintensification strategies for mCRC patients during COVID-19

(3:31)

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

(1:14)

Tanios Bekaii-Saab MD, FACP, discusses changes in treatment for CRC patients resulting from COVID-19

(6:43)

Tanios Bekaii-Saab, MD: Clinical Data Supporting Regorafenib in mCRC

(1:20)

Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer

(26)

Tanios Bekaii-Saab, MD, FACP, summarizes data regarding circulating tumor cells from ASCO GI 2021

(6:36)